Clinical trial Recruiting at 1 site Interventional Ages 21 and up

Cord plasma eye drops to treat neuropathic corneal pain

Official title: Evaluation of the Clinical Efficacy and Mechanisms of Cord Plasma Eye Drops in the Treatment of Neuropathic Corneal Pain

Run by Singapore Eye Research Institute · NCT07566806 · Data updated 2026-11-12

This trial will test whether cord plasma eye drops can reduce long-lasting nerve-related corneal pain in people with evidence of corneal nerve damage.

More Neuropathic Pain trials

Quick facts

Study typeInterventional
Ages21 Years and up
SexAll
Enrollment20 (estimated)
SponsorSingapore Eye Research Institute
Academic / other
Locations1 site (Singapore, Singapore)
StatusRecruiting
StartedSeptember 16, 2023
Main results expectedSeptember 15, 2026
Study endsSeptember 15, 2027
Registry record updatedMay 5, 2026
Trial IDNCT07566806 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients with at least three months of neuropathic corneal pain symptoms, corneal nerve abnormalities on IVCM, minimal corneal staining, and willingness to use cord plasma eye drops.

Probably not a fit

Patients with active ocular surface infection, epithelial defects, or primarily nociceptive (non-neuropathic) pain are unlikely to benefit from this treatment.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center interventional trial at the Singapore Eye Research Institute testing topical cord plasma eye drops in patients with neuropathic corneal pain lasting at least three months and corneal nerve abnormalities on in vivo confocal microscopy. Participants receive cord plasma eye drops and are followed for changes in pain symptoms, corneal nerve imaging (IVCM), and tear mediators to explore both clinical effect and mechanisms. Key eligibility requires persistent neuropathic symptoms, minimal surface staining, and imaging evidence of nerve damage; active ocular surface infection or epithelial defects are excluded. The study aims to determine whether the drops provide neurotrophic and anti-neuroinflammatory benefit beyond standard dry eye treatments.

Why it matters

Potential benefit: If successful, cord plasma eye drops could reduce neuropathic corneal pain and promote corneal nerve recovery for patients who do not respond to conventional treatments.

How similar studies have gone: Blood-derived eye drops (serum/plasma) have shown benefit for some ocular surface disorders, but applying cord plasma specifically for neuropathic corneal pain is relatively novel and not well-established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Persistent ocular pain or pain-like symptoms, including burning sensation, allodynia, photoallodynia, stinging, hyperalgesia, throbbing, shooting, sharp, cramping, gnawing, or a feeling of electric shock, with a minimum score of 30% for more than 3 questions in the OPAS questionnaire (see below section for OPAS questionnaire), for at least 3 months;
2. Presence of corneal nerve abnormalities, including microneuromas, beading, nerve tortuosity, decreased in corneal nerve fiber density (CNFD) or corneal nerve fiber length (CNFL), on IVCM images;
3. Minimal or no ocular surface fluorescein staining, with the National Eye Institute (NEI) and ocular surface Oxford score \<2;
4. Patients who will receive cord plasma eye drops treatment

Exclusion Criteria:

1. Presence of active ocular surface diseases, such as active infective keratitis, the presence of epithelial defect or any other conditions that may cause nociceptive pain
2. Active anterior or posterior blepharitis;
3. Presence of concomitant ocular diseases that may cause ocular pain, such as uveitis or other ocular inflammatory diseases;
4. Concurrent treatment with immunosuppressants, such as topical cyclosporin or steroid eye drops
5. Concurrent use of oral Nonsteroidal anti-inflammatory drugs (NSAID) or other medications that may affect the pain scores

Where it's running

  • Singapore Eye Research Institute
    Singapore, Singapore, Singapore
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.